Print

DEVELOPMENT PROGRAMS

Tanakan®

The Group is endeavouring to validate the clinical benefits of EGb 761®, Ginkgo biloba extract, present in Tanakan® for the treatment of cognitive impairment in elderly patients with or without predementia or dementia.

The Group is sponsoring three studies in Europe:

• The GuidAge study evaluating the efficacy of EGb 761® in the prevention of Alzheimer’s disease in patients aged 70 years or older having spontaneously complained of memory problems to their GP; the study was completed in 2010 and the publication of the results is in preparation. The primary efficacy endpoint was not reached, however, the analysis of subgroups under the protocol, particularly patients receiving long-term treatment, showed statistically significant results which are undergoing further evaluation by independent experts.
• A study evaluating the effect of EGb 761® on cerebral glucose metabolism, assessed by FDG-PET scan (in collaboration with the CEA), in patients with spontaneous complaints of amnesia and in patients with Alzheimer’s disease.
• A proof of concept study evaluating the effect of EGb 761® on muscle energy function and mitochondrial activity by MRI spectroscopy of children with a rare orphan genetic disease, Friedreich’s ataxia.